TOTAL SYNTHESES OF NAAMINE A and NAAMIDINE A, MARINE IMIDAZOLE ALKALOIDS

Shunsaku Ohta,* Naoki Tsuno, Seikou Nakamura, Norio Taguchi, Masayuki Yamashita, Ikuo Kawasaki, and Mieko Fujieda

Kyoto Pharmaceutical University, Misasagi Yamashinaku, Kyoto 607-8414, Japan, e-mail: sohta@mb.kyoto-phu.ac.jp

Abstract - The first total syntheses of naamine A (4) and naamidine A (5), marine imidazole alkaloids, were achieved through twelve and thirteen steps of reactions, respectively, starting from 1-methyl-2-phenylthio-1*H*-imidazole (17).

Recently, many marine imidazole alkaloids such as 1 - 10 in Table 1 have been isolated from sponges, and their antitumour and antibacterial activities have been also found.^{1,2} Structural characteristics of these alkaloids are that one or two alkoxybenzyl group(s) locates at the 1-, 4- and/or 5-positions of the 1*H*-imidazole ring and the 2-position is substituted with a primary amino group or a (1-methyl-2,5-dioxo-3-imidazolin-4-yl)amino moiety² (Table 1).

Hitherto, we have reported the total synthesis of several marine imidazole alkaloids such as nortopsentins A - D,³ topsentin,⁴ kealiiquinone (10),⁵ and clathridine A(2).⁶ In this paper, we would like to report the first total syntheses of naamine A (4) and naamidine A (5) starting from 1-methyl-2-phenyl-thio-1*H*-imidazole (17).

In previous papers, we reported a procedure for the preparation of 2-aminoimidazoles and preclathridine A(2) by using a reaction of 2-bromoimidazole with sodium azide or trimethysilyl azide (TMSN₃) in the



Name	Compd No.	\mathbf{R}^1	R^2	\mathbf{R}^4	R^5
Dorimidazole	1	CH ₃	NH ₂	b	Н
Preclathridine A	2	CH ₃	NH ₂	b	Н
Isonaamine A	3	с	Н	b	Н
Naamine A	4	CH ₃	NH ₂	с	b
Naamidine A	5	CH ₃	a	с	b
Isonaamidine A	6	b	a	b	b
Pyrronaamidine A	7	CH ₃	a	с	e
Clathridine A	8	CH ₃	a	d	Н
Clathridine B	9	CH ₃	a	d	d

Table 1. Several Marine Imidazole Alkaloids²



presence of an appropriate palladium complex followed by catalytic hydrogenation of the intermediate 2-azidoimidazoles.⁷ However, subsequent investigations indicated that the reported procedure did not always give good results probably because of the relatively high substrate specificity of the palladium complex used. Therefore, we searched for more general methods for the introduction of a primary amino group into the 2-position of 1-methylbenzimidazole. First, we examined Curtius rearrangement to the imidazole system (Route A in Scheme 1). The hydrazide (**13**), derived from **12**,⁷ was treated with nitrous acid followed by heating the intermediate acyl azide in toluene and subsequent hydrolysis with concentrated hydrochloric acid to give 2-amino-1-methylbenzimidazole (**16**). However, overall yield of **16** from **11** *via* Route A was too low to achieve the total synthesis of **5**.



Scheme 1

Next, we also tried the conversion of the bromide $(14)^8$ to the azide (15), in which the bromide (14) was treated with sodium azide in the presence of tributyltin chloride, 15-crown-5 ether and an appropriate palladium catalyst in tetrahydrofuran (THF) (Route B in Scheme 1).⁹ As shown in Table 2, the combination of TMSN₃ and PdCl₂[P(*o*-tolyl)₃]₂ was not effective (Entries 3 ~ 5), while that of NaN₃, PdCl₂(PPh₃)₂, and 15-crown-5 ether gave the best result (81.2% yield of **15**), though the reaction took 48 h to complete. (Entry 2).

Entry	XN_3	Pd-Catalyst	Coadditive	Reaction Time (h)	Yield of 15 (%) ^a
1	NaN ₃	PdCl ₂ (PPh ₃) ₂	None	48	73.2
2	NaN ₃	$PdCl_2(PPh_3)_2$	15-Crown ^b	48	81.2
3	NaN ₃	$PdCl_2[P(o-tolyl)_3]_2$	15-Crown ^b	48	No Reaction
4	NaN ₃	PdCl ₂ [P(o-tolyl) ₃] ₂	15-Crown ^b	72	No Reaction
5	TMSN ₃	PdCl ₂ (PPh ₃) ₂	None	48	No Reaction

Table 2.Conversion of the Bromide (14) to the Azide (15)

a: Isolated yields. b: 15-Crown-5 ether.

Moreover, the preparation of 16 via Route C in Scheme 1 was examined. 2-Lithio-1-methyl-

benzimidazole was quenched with tosyl azide or trisyl azide to give the oily 2-azidobenzimidazole (**15**) in 90.0 or 53.2% yield, respectively. Thus, we were able to develop several applicable methods for the introduction of an azide group into the 2-position of the imidazole ring. The azide (**15**) could be hydrogenated over palladium-charcoal to **16** in high yield.

The preparation of a naamine A precursor (26) was started from 1-methyl-2-phenylthio-1*H*-imidazole $(17)^{10}$ as shown in Scheme 2. Reaction of 4-methoxymethoxybenzaldehyde with the 5-lithio derivative of 17 gave the alcohol (18), which was subjected to protection of the OH group with *tert*-butyldimethylsilyl (TBS) group in the usual manner, followed by bromination of the 4-position with *N*-bromosuccinimide (NBS) to give the bromide (20) in 74.5% yield from 17. The 4-position in 20 was lithiated by treatment with *tert*-butyllithium, followed by quenching with 4-methoxybenzaldehyde to



Scheme 2

give the tetrasubstituted imidazole (21), which was desilylated by treatment with tetrabutylammonium fluoride (TBAF) to afford a diastereomeric mixture (ratio: about 1/1 on the basis of ¹H-NMR) of the diol (22) in 50.6% yield from 20. Reduction of 22 with nickel boride¹¹ gave a mixture of the 2-unsubstituted diol (23) (31.2% yield) and the 2-unsubstituted monool (24) (42.7% yield); however, reductive desulfurization of 22 with Raney nickel (W-2) or sodium metal in liquid ammonia did not proceed at all. The compounds 23 and 24 were each further treated with zinc powder in *conc.*-HCl - acetic acid at 80 to reduce to 4,5-dibenzylimidazole (25),¹² and the phenolic hydroxy group of 25 was silylated with TBS chloride in the usual manner to give 26.



Naamidine A (5, 43.5%)

The next steps were lithiation of the 2-position of the TBS ether (**26**) with *n*-butyllithium and subsequent introduction of an azide group with trisyl azide; however, most of the starting material (**26**) was recovered. This result would be attributed to lithiation at the benzyl methylene group of the 5-position rather than the 2-position and difficulty in the subsequent approach of trisyl azide to the relatively hindered lithiated position. On the other hand, fortunately, bromination of the 2-position in **26** with NBS followed by lithiation with *tert*-butyllithium and subsequent treatment with trisyl azide proceeded to afford the azide (**28**) in 32.8% yield from **26**. Hydrogenation of the azide (**28**) over palladium-charcoal gave the amine (**29**) in 68.2 % yield, and the TBS group was removed by treatment with TBAF to give naamine A (**4**)^{24,13} in 70.0% yield. Conversion of **4** to naamidine A (**5**) was achieved by the condensation of **4** with 1-methylparabanic acid (**30**) in the presence of trimethylsilyl chloride and triethylamine as previously reported⁶ to give naamidine A (**5**) as yellow granules in 43.5% yield. The structure of the synthetic naamidine A (**5**) was confirmed by comparison of its ¹H-NMR, ¹³C-NMR, IR and MS spectral data with those of the natural naamidine A.^{2d, 14} (Scheme 3)

ACKNOWLEDGMENT

This research was financially supported in part by the Frontier Research Program of the Ministry of Education, Science, Sports and Culture of Japan.

EXPERIMENTAL

All melting points were measured with a Yanaco MP micro-melting points apparatus and are not corrected. IR were taken with a Shimadzu IR-435 spectrophotometer. ¹H-NMR was measured on a Varian XL-300 (¹H: 300 MHz, ¹³C: 75.4 MHz) and a Varian UNITY *INOVA* 400NB (¹H: 400 MHz, ¹³C: 100.6 MHz) with tetramethylsilane as an internal standard, and chemical shifts are reported in ppm. Low-resolution MS (LRMS) and high-resolution MS (HRMS) were measured on JEOL JMS-SX 102A QQ and JEOL JMS BU-20 spectrometers. Silica gel (Merck Art. 7734) and Silica Gel 60PF₂₅₄ (Nacalai Tesque) were used for column chromatography and preparative TLC (PTLC), respectively.

2-Ethoxycarbonyl-1-methylbenzimidazole (12)⁷ *n*-C₄H₉Li (1.6 M in *n*-hexane, 0.325 mL, 2.5 mmol) was added dropwise to a solution of 1-methylbenzimidazole (11; 264 mg, 2.00 mmol) in THF (2 mL) at -78under N₂ and the whole was stirred for 30 min at the same temperature. To the reaction mixture, a solution of ethyl chloroformate (239 mg, 2.20 mmol) in THF (4 mL) was added dropwise at -78 and the whole was stirred for 30 min. After addition of water (2 mL), the mixture was extracted with AcOEt. The organic layer was washed with water, dried over anhydrous sodium sulfate. After removal of the solvent under reduced pressure, the residue was purified by column chromatography (AcOEt / n-hexane = 1 / 3) to give 12. Yield, 110 mg (27.0%). Colorless powder (ethyl acetate *n*-hexane), mp 148.8~150.1 . IR (CHCl₃): 2965, 1782, 1720, 1687, 1654, 1610, 1522, 1404, 1454, ¹H-NMR (300 MHz in CDCl₃) δ: 1.50 (t, 3H, *J*=7.1 Hz, OCH₂CH₃), 4.17 (s, 3H, N-CH₃), 1229 cm^{-1} . 4.52 (q, 2H, J=7.1 Hz, O-CH₂-CH₃), 7.33~7.45 (m, 4H, Ar-H). HRMS m/z: Calcd for C₁₁H₁₂N₂O₂, 204.0899. Found, 204.0907 (M⁺).

1-Methylbenzimidazole-2-carboxylic Acid Hydrazide (13) A mixture of **12** (174 mg, 0.85 mmol), hydrazine monohydrate (255 mg, 5.10 mmol), and EtOH (1.5 mL) was refluxed overnight. After addition of water, the mixture was extracted with AcOEt. The organic phase was washed with water and dried over sodium sulfate. Evaporation of the solvent gave a solid mass, which was purified by column chromatography (AcOEt) to give **13**. Yield, 51 mg (31.4%). Colorless needles (AcOEt), mp 133.7~134.9 . IR (CHCl₃): 3396, 2980, 1674, 1610, 1509, 1462, 1392, 1329, 1257 cm⁻¹. ¹H-NMR (300 MHz in CDCl₃) δ : 4.23 (s, 3H, N-CH₃), 7.32~7.79 (m, 3H, Ar-H), 7.79 (d, 1H, *J*=1.2 Hz, Ar-H). HRMS *m/z*: Calcd for C₉H₁₀N₄O, 190.0854. Found, 190.0852 (M⁺).

2-Azido-1-methylbenzimidazole $(15)^{15}$ a) From 14 with NaN₃ NaN₃ (24 mg, 0.36 mmol) and 15-crown-5 ether (79 mg, 0.36 mmol) were added to a solution of tributyltin chloride (117 mg, 0.36 mmol) in THF (1 mL) under N₂, and the mixture was stirred for 2 h at rt. A solution of 14 (51 mg, 0.24 mmol) in THF (1 mL) and PdCl₂(PPh₃)₂ (8.0 mg, 0.01 mmol) were added to the mixture, and the whole was refluxed for 48 h. After addition of aqueous 10% KF solution (1 mL), the mixture was

extracted with AcOEt and the organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent gave a crystalline solid, which was purified by column chromatography (AcOEt / n-hexane = 1 / 2) to give **15** as pale yellow needles. Yield, 34 mg (81.2%). IR (CHCl₃): 2965, 2167, 1616, 1492, 1445, 1405, 1258 cm⁻¹. ¹H-NMR (300 MHz in CDCl₃) δ: 3.54 (s, 3H, N-CH₃), 7.19~7.26 (m, 3H, Ar-H), 7.60~7.63 (m, 1H, Ar-H). HRMS *m/z*: Calcd for C₈H₇N₅, 173.0700. Found, 173.0703 (M⁺). b) From 11 with TrsN₃ *n*-C₄H₉Li (1.6 M in *n*-hexane, 0.34 mL, 0.55 mmol) was added to a solution of **11** (66 mg, 0.50 mmol) in THF (2 mL) at -78 under N₂, and the mixture was stirred for 30 min. Trisyl azide (170 mg, 0.55 mmol) in THF (1.0 mL) was added to the mixture, and the whole was stirred for 30 min. After dilution with AcOEt (20 mL), the reaction mixture was washed with water (2 mL), and the separated organic phase was dried over anhydrous sodium sulfate. A solid mass, obtained by evaporation of the solvent, was purified by column chromatography (AcOEt / n-hexane = 1 / 2). Yield. 46 mg (53.2%).

c) From **11** with TsN_3 Reaction was carried out in a similar manner as that for b) except for use of TsN_3 (108 mg, 0.55 mmol) instead of $TrsN_3$. Yield, 78 mg (90.0%).

2-Amino-1-methylbenzimidazole (16)^{15,16} a) From **13** A solution of NaNO₂ (93 mg, 1.35 mmol) in water (1.0 mL) was added to an ice-cooled and stirred solution of 13 (52 mg, 0.27 mmol) in conc-HCl (0.5 mL), and the whole was stirred at rt for 1 h. The reaction mixture was basified with powdered K₂CO₃, and extracted with toluene. After evaporation of the solvent, the residual solid was dissolved in conc-HCl (1.0 mL) and the whole mixture was heated at 80 for 1 h. The mixture was basified with powdered K₂CO₃, and extracted with AcOEt. The organic phase was dried over sodium sulfate followed by evaporation under reduced pressure to give a solid mass. The residue was purified by column chromatography (CHCl₃ / MeOH = 10 / 1) to give 16. Yield, 22 mg (56.3%). Colorless needles (AcOEt - *n*-hexane), mp 196.4~197.3 (lit., mp 201~202). IR (CHCl₃): 3381, 2928, 1630, 1551, 1456, 1240, 1085 cm⁻¹. ¹H-NMR (300 MHz in CDCl₃) δ: 3.53 (s, 3H, N-CH₃), 7.04~7.16 (m, 3H, Ar-H), 7.38~7.40 (m, 1H, Ar-H). HRMS *m/z*: Calcd for C₈H₉N₃, 147.0800. Found, 147.0793 $(M^{+}).$

b) From **15** A mixture of **15** (65 mg, 0.38 mmol), 10% Pd-C (30 mg), and EtOH (3 mL) was stirred under hydrogen atmosphere of usual pressure at rt for 3 h. After removal of the catalyst by filtration, the filtrate was evaporated under reduced pressure to give a crystalline solid, which was purified by column chromatography (CHCl₃ / MeOH = 10 / 1) to give **16**. Yield 50 mg (89.5%).

5-[1-Hydroxy-1-(4-methoxymethoxyphenyl)methyl]-1-methyl-2-phenylthio-1*H*-imidazole (18)

n-C₄H₉Li (1.6 M in n-hexane, 26.6 mL, 42.5 mmol) was added dropwise to a solution of 2,2,6,6-tetramethylpiperidine (4.99 g, 35.4 mmol), DME (12 mL) and THF (4 mL) at -78 under N₂ atmosphere, and the mixture was stirred for 15 min. A solution of **17** (6.73 g, 35.4 mmol) in THF (5 mL) was added dropwise to the mixture, and the mixture was stirred for 1 h at -78 . A solution of 4-methoxymethoxybenzaldehyde (5.89 g, 35.4 mmol) in THF (5 mL) was added dropwise to the mixture and the whole was stirred at the same temperature for 2 h. After dilution with AcOEt (50 mL), the mixture was washed with water (10 mL), and the separated organic phase was dried over anhydrous sodium sulfate followed by evaporation under reduced pressure to give an oily residue. The crude product was purified by column chromatography (AcOEt / n-hexane = 1 / 1) to give **18**. Yield, 12.6 g (quant.). Colorless needles (AcOEt - *n*-hexane), mp 86.4~87.8 . IR (CHCl₃): 3547, 3239, 2940, ¹H-NMR (400 MHz in CDCl₃) δ : 3.47 (s, 6H, N-CH₃ and 1718, 1607, 1529, 1221, 1148, 1075 cm⁻¹. O-CH₃), 5.16 (s, 2H, O-CH₂-O), 5.76 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 6.72 (s, 1H, C4-H), 6.95~7.01 (m, 2H, Ar-H), 7.02~7.10 (m, 2H, Ar-H), 7.11~7.22 (m, 3H, Ar-H), 7.24~7.30 (m, 2H, Ar-H). HRMS m/z: Calcd for C₁₉H₂₀N₂O₃S, 356.1194. Found, 356.1199 (M⁺). Anal. Calcd for C₁₉H₂₀N₂O₃S: C, 64.02; H, 5.66; N, 7.86. Found: C, 64.42; H, 5.81; N, 7.60.

5-[1-tert-Butyl dimethyls iloxy-1-(4-methoxymethoxyphenyl) methyl]-1-methyl-2-phenyl thio-1H-methyl-2-phenyl thio-1H-methyl-

imidazole (19) *tert*-Butyldimethylsilyl cholide (TBSCl, 29.2 g, 194 mmol) was added to a solution of **18** (12.5 g, 35.1 mmol), and imidazole (18.0 g, 265 mmol) in DMF (100 mL) under N₂ atmosphere and ice-cooling, and the mixture was stirred at 60 overnight. After dilution with ether (200 mL), the mixture was washed with water (40 mL), and the separated organic layer was dried over anhydrous sodium sulfate. After removal of the solvent, the residue was purified by column chromatography

(AcOEt / *n*-hexane = 1 / 3) to give **19**. Colorless viscous oil. Yield, 16.5 g (quant.). IR (CHCl₃): 2935, 1607, 1581, 1503, 1474, 1454, 1248, 1215, 1164, 1072 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : -0.06 (s, 3H, Si-CH₃), 0.19 (s, 3H, Si-CH₃), 1.02 (s, 9H, Si-C(CH₃)₃), 3.43 (s, 3H, N-CH₃), 3.59 (s, 3H, O-CH₃), 5.29 (s, 2H, O-CH₂-O), 6.00 (s, 1H, Ar-C(OTBS)H-Ar), 7.25 (s, 1H, C4-H), 7.02~7.08 (m, 2H, Ar-H), 7.09~7.14 (m, 2H, Ar-H), 7.17~7.23 (m, 2H, Ar-H), 7.24~7.32 (m, 3H, Ar-H). HRMS *m*/*z*: Calcd for C₂₅H₃₄N₂O₃SSi, 470.2059. Found, 470.2055 (M⁺).

4-Bromo-5-[1-*tert***-butyldimethylsiloxy-1-(4-methoxymethoxyphenyl)methyl]-1-methyl-2-phenylthio** -*1H***-imidazole (20)** *N*-Bromosuccimide (18 mg, 0.10 mmol) was added to a solution of **19** (47 mg, 0.10 mmol) in THF (1 mL) at 0 , and the mixture was stirred for 3 h at 0 . The mixture was diluted with ether, washed with aqueous 5% Na₂S₂O₃ (2 mL), and the separated organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent gave an oily residue, which was purified by column chromatography (AcOEt*/n*-hexane = 1 / 5) to give **20** as a pale yellow viscous oil. Yield, 41 mg (74.5%). IR (CHCl₃): 2938, 1723, 1607, 1580, 1503, 1474, 1445, 1250, 1228, 1163, 1073 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) & -0.06 (s, 3H, Si-CH₃), 0.18 (s, 3H, Si-CH₃), 0.91 (s, 9H, Si-C(CH₃)₃), 3.47 (s, 3H, N-CH₃), 3.63 (s, 3H, O-CH₃), 5.16 (s, 2H, O-CH₂-O), 6.07 (s, 1H, Ar-C(OTBS)H-Ar), 6.99 (d, 2H, *J*=8.8 Hz, Ar-H), 7.08 (d, 2H, *J*=8.8 Hz, Ar-H), 7.14~7.33 (m, 5H, Ar-H). HRMS *m/z*: Calcd for C₂₅H₃₃N₂O₃BrSSi, 548.1164. Found, 548.1156 (M⁺).

5-[1-tert-Butyldimethylsiloxy-1-(4-methoxymethoxyphenyl)methyl]-4-[1-hydroxy-1-(4-methoxy-1

phenyl)methyl]-1-methyl-2-phenylthio-1*H*-imidazole (21) *tert*-C₄H₉Li (1.51 M in *n*-pentane, 0.26 mL, 0.40 mmol) was added to a solution of 20 (110 mg, 0.20 mmol) in ether (4 mL) at -78 under N₂ atmosphere, and the mixture was stirred for 30 min. *p*-Anisaldehyde (136 mg, 1.0 mmol) was added, and the whole was stirred at the same temperature for 3 h. After dilution with AcOEt (10 mL), the mixture was washed with water (3 mL), and the separated organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent gave an oily residue, which was purified by column chromatography (AcOEt / *n*-hexane = 1 / 2) to give a diastereomeric mixture (1:1) of **21** as a pale yellow viscous oil. Yield, 62 mg (51.1%). IR (CHCl₃): 3437, 2936, 1723, 1608, 1581, 1505, 1459, 1240,

1167, 1073, 1000 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : -0.30 (s, 3H, Si-CH₃), -0.09 (s, 3H, Si-CH₃), -0.04 (s, 3H, Si-CH₃), 0.16 (s, 3H, Si-CH₃), 0.86 (s, 9H, Si-C(CH₃)₃), 0.90 (s, 9H, Si-C(CH₃)₃), 3.26 (s, 3H, N-CH₃), 3.33 (s, 3H, N-CH₃), 3.44 (s, 3H, O-CH₃), 3.47 (s, 3H, O-CH₃), 3.78 (s, 3H, O-CH₃), 3.79 (s, 3H, O-CH₃), 5.11 (s, 2H, O-CH₂-O), 5.15 (s, 2H, O-CH₂-O), 5.83 (s, 1H, Ar-C(OTBS)H-Ar), 5.90 (s, 1H, Ar-C(OTBS)H-Ar), 5.97 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 6.09 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 6.82~6.89 (m, 6H, Ar-H), 6.90~6.98 (m, 4H, Ar-H), 7.00~7.29 (m, 12H, Ar-H), 7.36~7.46 (m, 4H, Ar-H). HRMS *m/z*: Calcd for $C_{33}H_{42}N_2O_5SSi$, 606.2583. Found, 606.2592 (M⁺).

5-[1-Hydroxy-1-(4-methoxymethoxyphenyl)methyl]-4-[1-hydroxy-1-(4-methoxyphenyl)methyl]-1-

methyl-2-phenylthio-1*H*-imidazole (22) Tetrabutylammonium fluoride (1.0 M in THF, 0.20 mL, 0.20 mmol) was added to a solution of 21 (121 mg, 0.20 mmol) in THF (1 mL) at rt and the mixture was stirred for 10 min. After dilution with AcOEt (10 mL), the mixture was washed with water (1 mL), and the separated organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent gave an oily residue, which was purified by column chromatography (AcOEt/*n*-hexane = 1 / 1) to give a diastereomeric mixture (1:1) of 22 as a pale yellow viscous oil. Yield, 97 mg (99.0%). IR (CHCl₃): 3305, 2974, 1724, 1608, 1580, 1505, 1474, 1448, 1235, 1213, 1167 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ: 3.23 (s, 3H, N-CH₃), 3.28 (s, 3H, N-CH₃), 3.44 (s, 3H, O-CH₃), 3.45 (s, 3H, O-CH₃), 3.72 (s, 3H, O-CH₃), 3.73 (s, 3H, O-CH₃), 5.10 (s, 2H, O-CH₂-O), 5.11 (s, 2H, O-CH₂-O), 5.70 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 5.92 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 5.95 (s, 1H, Ar-C(OH)<u>H</u>-Ar), 6.05 (s, 1H, Ar-C(OH)H-Ar), 6.70~6.77 (m, 4H, Ar-H), 6.81~6.88 (m, 4H, Ar-H), 6.91~7.02 (m, 8H, Ar-H), 7.03~7.18 (m, 6H, Ar-H), 7.19~7.30 (m, 4H, Ar-H). HRMS *m/z*: Calcd for C₂₇H₂₈N₂O₅S, 492.1719. Found, 492.1718 (M⁺).

5-[1-Hydroxy-1-(4-methoxymethoxyphenyl)methyl]-4-[1-hydroxy-1-(4-methoxyphenyl)methyl]-1methyl-1*H*-imidazole (23) and 5(4)-[1-Hydroxy-1-(4-methoxymethoxyphenyl)methyl]-4(5)-[1-(4methoxyphenyl)methyl]-1-methyl-1*H*-imidazole (24) Nickel(II) chloride hexahydrate (2.17 g, 9.12 mmol) and NaBH₄ (1.23 g, 32.6 mmol) were added to a solution of 22 (642 mg, 1.30 mmol) in MeOH / THF = 3 / 1 (8 mL), and the mixture was stirred at rt for 1.5 h. The reaction mixture was passed through a florisil column to remove Ni colloid. The eluate was diluted with water (20 mL) and extracted with AcOEt (50 mL). The organic phase was dried over anhydrous sodium sulfate and evaporated to give an oily residue, which was purified by column chromatography (CHCl₃ / MeOH = 20 / 1) to give a diastereomeric mixture (1:1) of 23 and 24. 23: Colorless oil. Yield, 156 mg (31.2%). IR (CHCl₃): 3324, 2980, 1723, 1607, 1505, 1236, 1167, 1074, 1028 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ: 3.27 (s, 3H, N-CH₃), 3.28 (s, 3H, N-CH₃), 3.46 (s, 3H, O-CH₃), 3.46 (s, 3H, O-CH₃), 3.74 (s, 3H, O-CH₃), 3.75 (s, 3H, O-CH₃), 5.14 (s, 4H, O-CH₂-O), 5.70 (s, 1H, Ar-C(OH)H-Ar), 5.79 (s, 1H, Ar-C(OH)H-Ar), 5.98 (s, 1H, Ar-C(OH)H-Ar), 5.98 (s, 1H, Ar-C(OH)H-Ar), 6.79 (d, 4H, J=8.6 Hz, Ar-H), 6.92 (d, 4H, J=8.8 Hz, Ar-H), 7.19 (s, 1H, C2-H), 7.20 (s, 1H, C2-H), 7.07 (dd, 4H, J=8.4, 2.4 Hz, Ar-H), 7.24 - 7.40 (m, 4H, Ar-H). HRMS m/z: Calcd for C₂₁H₂₄N₂O₅, 384.1685. Found, 384.1691 $(M^{+}).$ **24**: Colorless oil. Yield, 205 mg (42.7%). IR (CHCl₃): 3089, 2981, 2820, 1607, 1581, 1504, 1459, 1234, 1166, 1075, 1002 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ: 3.28 (s, 3H, N-CH₃), 3.47 (s, 3H, O-CH₃), 3.74 (s, 3H, O-CH₃), 3.77 (d, 1H, J=15.6 Hz, Ar-CH₂-Ar), 3.82 (d, 1H, J=15.6 Hz, Ar-CH₂-Ar), 5.15 (s, 2H, O-CH₂-O), 6.00 (s, 1H, r-C(OH)<u>H</u>-Ar), 6.75 (d, 2H, J=8.6 Hz, Ar-H), 6.94 (d, 2H, J=8.8 Hz, Ar-H), 7.09~7.18 (m, 5H, Ar-H). HRMS m/z: Calcd for C₂₁H₂₄N₂O₄, 368.1736. Found, 368.1732 $(M^{+}).$

4-[1-(4-Methoxyphenyl)methyl]-5-[1-(4-hydroxyphenyl)methyl]-1-methyl-1*H***-imidazole (25) a) From 24**. Zn powder (5.0 g) were added to a mixture of acetic acid (20 mL), *conc.*-HCl (5 mL) and **24** (598 mg, 1.63 mmol), and the whole was stirred at 80 for 1 h. The reaction mixture was filtered through a cotton plug, and the filtrate was evaporated under reduced pressure. After addition of water (5 mL), K₂CO₃ powder was added to basify, and the whole was extracted with AcOEt. The organic phase was dried over anhydrous sodium sulfate and evaporated to give an oily residue, which was purified by column chromatography (CHCl₃ / MeOH = 30 / 1) to give **25**. Yield, 347 mg (69.4%). Colorless crystals (AcOEt – MeOH), mp 222.8 - 225.2 . IR (KBr): 3400, 2900, 1607, 1507, 1450, 1242, 1170, 1080 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : 3.33 (s, 3H, N-CH₃), 3.75 (s, 3H, O-CH₃), 3.86 (s, 2H, Ar-CH₂-Ar), 3.87 (s, 2H, Ar-CH₂-Ar), 6.68 (d, 2H, *J*=8.4 Hz, Ar-H), 6.78 (d, 2H, *J*=8.6 Hz, Ar-H), 6.83 (d, 2H, J=8.6 Hz, Ar-H), 7.15 (d, 2H, J=8.6 Hz, Ar-H), 7.41 (s, 1H, C2-H). HRMS m/z: Calcd for C₁₉H₂₀N₂O₂, 308.1525. Found, 308.1521 (M⁺). Anal. Calcd for C₁₉H₂₀N₂O₂: C, 74.00; H, 6.54; N, 9.08. Found: C, 73.76; H, 6.66; N, 8.92.

b) From 23. Reaction was carried out in a similar manner as that for a) except for use of 23 (9 mg, 0.02 mmol) instead of 24. Yield, 5 mg (71.4%).

5-[1-(4-tert-Butyldimethylsiloxyphenyl)methyl]-4-[1-(4-methoxyphenyl)methyl]-1-methyl-1H-

imidazole (26) This compound was prepared in a similar manner as that used for preparation of 19 except for use of 25 (257 mg, 0.83 mmol) instead of 18. The obtained crude product was purified by column chromatography (CHCl₃/ MeOH = 30 / 1) to give 26 as a pale yellow viscous oil. Yield, 306 mg (87.5%). IR (CHCl₃): 2915, 1605, 1505, 1459, 1247, 1223, 1167, 1097, 1032 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : 0.17 (s, 6H, Si-CH₃), 0.97 (s, 9H, Si-C(CH₃)₃), 3.31 (s, 3H, N-CH₃), 3.76 (s, 3H, O-CH₃), 3.86 (s, 2H, Ar-CH₂-Ar), 3.87 (s, 2H, Ar-CH₂-Ar), 6.71 (d, 2H, *J*=8.6 Hz, Ar-H), 6.80 (d, 2H, *J*=8.6 Hz, Ar-H), 6.85 (d, 2H, *J*=8.6 Hz, Ar-H), 7.16 (d, 2H, *J*=8.6 Hz, Ar-H), 7.26 (s, 1H, C2-H). HRMS *m/z*: Calcd for C₂₅H₃₄N₂O₂Si, 422.2389. Found, 422.2379 (M⁺).

2-Bromo-5-[1-(4-tert-butyldimethylsiloxyphenyl)methyl]-4-[1-(4-methoxyphenyl)methyl]-1-methyl-

1*H***-imidazole (27)** *N*-Bromosuccinimide (148 mg, 0.83 mmol) was added to a solution of **26** (352 mg, 0.83 mmol) in THF (5 mL) at 0 and the mixture was stirred for 1 h at 0 . After dilution with AcOEt (10 mL), the mixture was washed with aqueous 5% Na₂S₂O₃ (2 mL), and the separated organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent gave an oily residue, which was purified by column chromatography (AcOEt / *n*-hexane = 1 / 2) to give **27** as a pale yellow viscous oil. Yield, 301 mg (72.4%). IR (CHCl₃): 2932, 1723, 1605, 1504, 1482, 1245, 1170, 1099, 1033 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : 0.18 (s, 6H, Si-CH₃), 0.97 (s, 9H, Si-C(CH₃)₃), 3.26 (s, 3H, N-CH₃), 3.76 (s, 3H, O-CH₃), 3.84 (s, 2H, Ar-CH₂-Ar), 3.86 (s, 2H, Ar-CH₂-Ar), 6.71 (d, 2H, *J*=8.6 Hz, Ar-H), 6.78 (d, 2H, *J*=8.8 Hz, Ar-H), 6.84 (d, 2H, *J*=8.8 Hz, Ar-H), 7.12 (d, 2H, *J*=8.8 Hz, Ar-H). ¹³C-NMR (100.6 MHz in CDCl₃) δ : 18.1, 25.6, 29.2, 29.7, 32.2, 32.9, 55.2, 113.8, 118.4, 120.2, 128.6, 128.8, 129.4, 130.2, 132.5, 139.5, 154.3, 157.9. HRMS *m*/*z*: Calcd for C₂₅H₃₃N₂O₂BrSi, 500.1495.

Found, 500.1486 (M⁺).

$\label{eq:2-Azido-5-[1-(4-tert-butyldimethylsiloxyphenyl)methyl]-4-[1-(4-methoxyphenyl)methyl]-1-methyl-1-met$

tert-C₄H₉Li (1.51 M in *n*-pentane, 0.44 mL, 0.67 mmol) was added dropwise to a 1*H*-imidazole (28) solution of 27 (160 mg, 0.32 mmol) in ether (1 mL) at -78, and the mixture was stirred for 30 min. Trisylazide (109 mg, 0.35 mmol) was added to the mixture at -78 , and the whole was stirred for 1 h. After dilution with AcOEt (10mL), the mixture was washed with water (2 mL), and the separated organic phase was dried over sodium sulfate. Evaporation of the solvent gave an oily residue, which was purified by column chromatography (AcOEt / n-hexane = 1 / 5) to give 28 as a pale vellow viscous oil and 27 (55 mg, 34.4%). Yield, 67 mg (45.3%). IR (CHCl₃): 2912, 2119, 1604, 1503, 1250, 909 cm^{-1} . ¹H-NMR (400 MHz in CDCl₃) δ: 0.17 (s, 6H, Si-CH₃), 0.97 (s, 9H, Si-C(CH₃)₃), 3.06 (s, 3H, N-CH₃), 3.77 (s, 3H, O-CH₃), 3.78 (s, 2H, Ar-CH₂-Ar), 3.83 (s, 2H, Ar-CH₂-Ar), 6.71 (d, 2H, J=8.4 Hz, Ar-H), 6.80 (d, 2H, J=8.4 Hz, Ar-H), 6.85 (d, 2H, J=8.4 Hz, Ar-H), 7.12 (d, 2H, J=8.8 Hz, Ar-H). ¹³C-NMR (100.6 MHz in CDCl₃) δ: 18.2, 25.7, 28.7, 29.4, 32.7, 55.2, 113.8, 120.2, 123.7, 124.9, 128.8, 129.4, 130.7, 132.7, 136.2, 138.9, 154.2, 157.9. HRMS *m/z*: Calcd for C₂₅H₃₃N₅O₂Si, 463.2403. Found, 463.2405 (M⁺).

2-Amino-5-[1-(4-tert-butyldimethylsiloxyphenyl)methyl]-4-[1-(4-methoxypheny)methyl]-1-methyl-

1*H***-imidazole (29)** This compound was prepared in a similar manner as that used for the preparation of **16** from **15** except for use of **28** (34 mg, 0.074 mmol) instead of **15**. The crude oily product was purified by column chromatography (CHCl₃ / MeOH = 7 / 3) to give **29** as a pale yellow viscous oil. Yield, 22 mg (68.2%). IR (CHCl₃): 3288, 2916, 1723, 1667, 1605, 1505, 1459, 1246, 1220 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ : 0.18 (s, 6H, Si-CH₃), 0.97 (s, 9H, Si-C(CH₃)₃), 3.05 (s, 3H, N-CH₃), 3.76 (s, 3H, O-CH₃), 3.76 (s, 2H, Ar-CH₂-Ar), 3.78 (s, 2H, Ar-CH₂-Ar), 5.23 (br, 2H, NH₂), 6.73 (d, 2H, *J*=8.8 Hz, Ar-H), 6.79 (d, 2H, *J*=8.8 Hz, Ar-H), 6.89 (d, 2H, *J*=8.8 Hz, Ar-H), 7.15 (d, 2H, *J*=8.4 Hz, Ar-H). ¹³C-NMR (100.6 MHz in CDCl₃) δ : 18.2, 28.4, 29.1, 31.3, 38.7, 55.2, 113.9, 120.3, 120.8, 128.8, 129.5, 130.5, 130.9, 131.9, 154.3, 158.0. HRMS *m/z*: Calcd for C₂₅H₃₅N₃O₂Si, 437.2498. Found, 437.2508 (M⁺).

TBAF (1.0 M in THF, 0.032 mL, 0.032 mmol) was added to a solution of 29 (14 mg, Naamine A (4) 0.032 mmol) in THF(1 mL) at rt under N₂ atmosphere, and the mixture was stirred for 10 min. After dilution with CHCl₃ (10 mL), the mixture was washed with water (1 mL), and the separated organic phase was dried over anhydrous sodium sulfate. Removal of the solvent under reduced pressure gave an oily residue, which was purified by column chromatography (CHCl₃/MeOH = 7/3) to give 4 as a pale yellow powder. Yield, 7 mg (70.0%). mp 202.0 - 204.5 IR (KBr): 3350, 1668, 1568, 1507, 1417, 1240 cm⁻¹. ¹H-NMR (400 MHz in CDCl₃) δ: 3.05 (s, 3H, N-CH₃), 3.65 (s, 3H, Ar-CH₃), 3.72 (s, 2H, Ar-CH₂-Ar), 3.73 (s, 2H, Ar-CH₂-Ar), 6.72 - 6.82 (m, 6H, Ar-H), 7.10 (d, 2H, J=8.4 Hz, Ar-H). HRMS m/z: Calcd for C₂₁H₁₉N₃O₂, 323.1634. Found, 323.1643 (M⁺). These data were almost agreed with those of the natural naamine A.^{2d, 13}

Naamidine A (5) A mixture of 1-methylparabanic acid (30; 7 mg, 0.053 mmol), 4-N,N-dimethylaminopyridine (1 mg), imidazole (4 mg, 0.059 mmol), triethylamine (11 mg, 0.11 mmol), and trimethylsilyl chloride (12 mg, 0.111 mmol) in CHCl₃ (0.5 mL) was stirred for 5 min under ice-cooling and N₂ atmosphere, and then the stirring was continued for 2 h at rt. A solution of naamine A (4; 17 mg, 0.053 mmol) in CHCl₃(1 mL) was added to the mixture, and the whole was refluxed for 72 h. After dilution with CHCl₃ (10 mL), the mixture was washed with water (1 mL), and the separated organic phase was dried over anhydrous sodium sulfate. The organic phase was evaporated under reduced pressure to give a crystalline residue, which was triturated with CHCl₃ followed by filtration to give pure **5** as yellow granules. Yield, 10 mg (43.5%). mp 186.5 – 190.0 . IR (CHCl₃): 3410, 1725, 1668, ¹H-NMR (400 MHz in CDCl₃ + CD₃OD) δ: 3.04 (s, 3H, N-CH₃), 1635, 1608, 1508, 1440, 1240 cm⁻¹. 3.15 (s, 3H, N-CH₃), 3.78 (s, 3H, O-CH₃), 3.79 (s, 2H, Ar-CH₂-Ar), 3.83 (s, 2H, Ar-CH₂-Ar), 6.75 (d, 2H, J=8.4 Hz, Ar-H), 6.82 (d, 2H, J=8.8 Hz, Ar-H), 6.91 (d, 2H, J=8.4 Hz, Ar-H), 7.13 (d, 2H, J=8.4 Hz, ¹³C-NMR (75.4 MHz in CDCl₃ + CD₃OD) δ : 24.9, 27.4, 28.4, 29.7, 54.5, 113.4, 115.0, 127.5, Ar-H). 128.4, 128.8, 129.9, 130.4, 131.8, 146.6, 148.4, 155.3, 157.8, 162.5. HRMS m/z: Calcd for C₂₃H₂₃N₅O₄, 433.1750. Found, 433.1742 (M⁺). These data were almost agreed with those of the natural naamidine A.^{2d, 14}

REFERENCES AND NOTES

- 1. J. R. Lewis, Nat. Prod. Rep., 1992, 9, 81; D. J. Faulkner, ibid., 1992, 9, 323.
- a) P. Ciminiello, E. Fattorusso, S. Magno, and A. Mangoni, *Tetrahedron*, 1989, 45, 3873; b) K. A. Alvi, B. M. Peters, L. M. Hunter, and P. Crews, *ibid.*, 1993, 49, 329; c) S. Carmely and Y. Kashman, *ibid.*, 1987, 28, 3003; d) S. Carmely, M. Ilan, and Y. Kashman, *Tetrahedron*, 1989, 45, 2193.
- 3. I. Kawasaki, M. Yamashita, and S. Ohta, *J. Chem. Soc., Chem. Commun.*, **1994**, 2085; I. Kawasaki, M. Yamashita, and S. Ohta, *Chem. Pharm. Bull.*, 1996, **44**, 1831.
- I. Kawasaki, H. Katsuma, Y. Nakayama, M. Yamashita, and S. Ohta, *Heterocyclic Commun.*, 1996, 2, 189;
 I. Kawasaki, H. Katsuma, Y. Nakayama, M. Yamashita, and S. Ohta, *Heterocycles*, 1998, 48, 1887.
- I. Kawasaki, N. Taguchi, T. Yamamoto, M. Yamashita, and S. Ohta, *Tetrahedron Lett.*, 1995, 36, 8251;
 I. Kawasaki, N. Taguchi, M. Yamashita, and S. Ohta, *Chem. Pharm. Bull.*, 1997, 45, 1393.
- 6. S. Ohta, N. Tsuno, K. Maeda, S. Nakamura, N. Taguchi, M. Yamashita, and I. Kawasaki, *Tetrahedron Lett.*, in press.
- 7. F. H. Pinkerton and S. F. Thamas, J. Heterocycl. Chem., 1972, 9, 67.
- 8. I. Kawasaki, N. Taguchi, Y. Yoneda, M. Yamashita, and S. Ohta, Heterocycles, 1996, 43, 1375.
- 9. S. G. Anil and S. L. Buchwald, J. Am. Chem. Soc., 1994, 116, 7901.
- S. Ohta, T. Yamamoto, I. Kawasaki, M. Yamashita, H. Katsuma, R. Nasako, K. Kobayashi, and K. Ogawa, *Chem. Pharm. Bull.*, 1992, 40, 2681.
- 11. T. G. Back, D. L. Baron, and K. Yang, J. Org. Chem., 1993, 58, 2407.
- Catalytic hydrogenolysis of the benzylic hydroxyl group for 23 and 24 in the presence of 5 or 10%
 Pd-C did not proceed at all.
- 13. The reported data for the natural naamine A (ref. 2d): IR (KBr): 3500 (br), 2920, 1670, 1615 cm⁻¹.
 ¹H-NMR (DMSO-*d*₆) δ: 3.15 (br s, 3H), 3.69 (s, 3H), 3.79 (br s, 2H), 3.84 (br s, 2H), 6.70 (d, 2H, *J*=8.6 Hz), 6.83 (d, 2H, *J*=8.6 Hz), 6.89 (d, 2H, *J*=8.6 Hz), 7.16 (d, 2H, *J*=8.6 Hz), 7.60 (br s, 2H).

Mp was not reported in ref. 2d.

- 14. The reported data for the natural naamidine A (ref. 2d): Yellow foaming oil. IR (KBr): 3650-3100 (br), 2930, 1707, 1570, 1510, 1440, 1250, 1170, 1025 cm⁻¹. ¹H-NMR (CDCl₃ + CD₃OD) δ: 3.13 (s, 3H), 3.48 (br s, 3H), 3.77 (s, 3H), 3.88 (br s, 2H), 3.91 (br s, 2H), 6.72 (d, 2H *J*=8.6 Hz), 6.81 (d, 2H *J*=8.6 Hz), 6.84 (d, 2H *J*=8.6 Hz), 7.11 (d, 2H *J*=8.6 Hz). ¹³C-NMR (CDCl₃ + CD₃OD) δ: 24.4, 28.2, 29.6, 31.3, 55.0, 113.9, 115.6, 126.7, 127.4, 128.7, 129.1, 130.7, 132.9, 146.2, 148.4, 155.6, 158.3, 163.3. Mp was not reported in ref. 2d.
- Y. Shiokawa and S. Ohki, *Chem. Pharm. Bull.*, 1971, **19**, 401; N. P. Bednyagina and I. Y. Postovskii, *Zh. Obshch. Khim.*, 1960, **30**, 1431 [*CA*, **55**; 1586h (1961)].
- 16. Y. Kikugawa, Synthesis, 1981, 124; A. M. Simonov and N. D. Vitkevich, Zh. Obshch. Khim., 1960, 30, 590 [CA, 54; 24677i (1960)].